Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Return on Equity: 2015-2025

Historic Return on Equity for Ascendis Pharma A (ASND) over the last 11 years, with Sep 2025 value amounting to 2.24%.

  • Ascendis Pharma A's Return on Equity rose 26.00% to 2.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.24%, marking a year-over-year increase of 26.00%. This contributed to the annual value of 3.02% for FY2024, which is 1227.00% up from last year.
  • Per Ascendis Pharma A's latest filing, its Return on Equity stood at 2.24% for Q3 2025, which was up 64.72% from 1.36% recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Return on Equity ranged from a high of 15.73% in Q3 2023 and a low of -4.46% during Q4 2022.
  • Over the past 3 years, Ascendis Pharma A's median Return on Equity value was 2.65% (recorded in 2025), while the average stood at 3.71%.
  • Over the last 5 years, Ascendis Pharma A's Return on Equity had its largest YoY gain of 1,111bps in 2024, and its largest YoY loss of 1,376bps in 2024.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Return on Equity stood at -0.42% in 2021, then slumped by 404bps to -4.46% in 2022, then skyrocketed by 875bps to 4.30% in 2023, then slumped by 61bps to 3.69% in 2024, then grew by 26bps to 2.24% in 2025.
  • Its Return on Equity was 2.24% in Q3 2025, compared to 1.36% in Q2 2025 and 2.32% in Q1 2025.